Dustin A Deming Selected Research

sapanisertib

1/2022	Inhibition of B-cell lymphoma 2 family proteins alters optical redox ratio, mitochondrial polarization, and cell energetics independent of cell state.
1/2019	MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.
1/2019	Activating Mutations in Pik3ca Contribute to Anal Carcinogenesis in the Presence or Absence of HPV-16 Oncogenes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dustin A Deming Research Topics

Disease

36	Neoplasms (Cancer) 10/2022 - 06/2012
18	Colorectal Neoplasms (Colorectal Cancer) 12/2020 - 06/2012
8	Colonic Neoplasms (Colon Cancer) 01/2022 - 01/2014
3	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 02/2017
2	Breast Neoplasms (Breast Cancer) 03/2021 - 01/2020
2	Rectal Neoplasms (Rectal Cancer) 12/2020 - 01/2017
2	Carcinogenesis 01/2019 - 01/2014
2	Adenoma (Adenomas) 01/2018 - 01/2014
1	Lymphoma (Lymphomas) 10/2022
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022
1	Pancreatic Neoplasms (Pancreatic Cancer) 11/2021
1	Prostatic Neoplasms (Prostate Cancer) 09/2021
1	Residual Neoplasm 12/2020
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 10/2020
1	Triple Negative Breast Neoplasms 01/2020
1	Lung Neoplasms (Lung Cancer) 01/2020
1	Neutropenia 01/2019
1	Anus Neoplasms (Anal Cancer) 01/2019
1	Cytopenia 01/2019
1	Microsatellite Instability 11/2017
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 06/2017
1	Neoplasm Metastasis (Metastasis) 01/2016
1	Fatigue 04/2014
1	Adenocarcinoma 01/2014
1	Intestinal Neoplasms (Intestinal Cancer) 01/2014
1	Carcinoma (Carcinomatosis) 01/2014
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 08/2013
1	Hyperplasia 06/2012

Drug/Important Bio-Agent (IBA)

7	Pharmaceutical PreparationsIBA 01/2022 - 01/2020
7	Biomarkers (Surrogate Marker)IBA 09/2021 - 01/2016
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2012
3	ErbB Receptors (EGF Receptor)IBA 10/2022 - 06/2017
3	sapanisertibIBA 01/2022 - 01/2019
3	Temozolomide (Temodar)FDA LinkGeneric 10/2020 - 02/2017
3	veliparibIBA 08/2019 - 01/2017
3	CateninsIBA 01/2019 - 01/2014
3	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2019 - 06/2012
3	Capecitabine (Xeloda)FDA Link 01/2017 - 08/2013
2	DNA (Deoxyribonucleic Acid)IBA 12/2020 - 04/2019
2	Phosphotransferases (Kinase)IBA 01/2019 - 06/2012
2	dactolisibIBA 01/2019 - 01/2017
2	Cetuximab (Erbitux)FDA Link 06/2017 - 04/2016
1	copanlisibIBA 10/2022
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2022
1	navitoclaxIBA 01/2022
1	TOR Serine-Threonine KinasesIBA 01/2022
1	entrectinibIBA 01/2022
1	Interferon-gamma (Interferon, gamma)IBA 11/2021
1	Profilins (Profilin)IBA 11/2021
1	Androgen Receptors (Androgen Receptor)IBA 09/2021
1	trifluridine tipiracil drug combinationIBA 10/2020
1	CrizotinibIBA 01/2020
1	cabozantinibIBA 01/2020
1	9,10-Dimethyl-1,2-benzanthraceneIBA 01/2019
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2019
1	CarcinogensIBA 01/2019
1	Everolimus FDA Link 01/2019
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019
1	Mitogen-Activated Protein KinasesIBA 01/2019
1	AntibodiesIBA 12/2018
1	Cyclic AMP (AMP, Cyclic)IBA 01/2018
1	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2018
1	Immunologic Factors (Immunomodulators)IBA 11/2017
1	Panitumumab (Vectibix)FDA Link 06/2017
1	Monoclonal AntibodiesIBA 06/2017
1	human ERBB2 proteinIBA 06/2017
1	RamucirumabIBA 06/2017
1	Bevacizumab (Avastin)FDA Link 06/2017
1	Trastuzumab (Herceptin)FDA Link 06/2017
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2017
1	LY3023414IBA 01/2017
1	MTOR InhibitorsIBA 01/2017
1	Proteoglycans (Proteoglycan)IBA 01/2017
1	chenodeoxycholate sulfate conjugate (CDCS)IBA 01/2017
1	Versicans (Versican)IBA 01/2017
1	AZD 6244IBA 04/2016
1	Cre recombinaseIBA 10/2015
1	2,2- dimethyl- N- (6- oxo- 6,7- dihydro- 5H- dibenzo(b,d)azepin- 7- yl)- N'- (2,2,3,3,3- pentafluoropropyl)malonamideIBA 02/2015
1	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 02/2015
1	Bortezomib (Velcade)FDA Link 04/2014
1	Vorinostat FDA Link 04/2014
1	CLR1502IBA 01/2014
1	CLR1404IBA 01/2014
1	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2014
1	Ether (Diethyl Ether)IBA 01/2014
1	Dextrans (Dextran)FDA Link 01/2014
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2014
1	Calcibiotic Root Canal SealerIBA 01/2014
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 08/2013
1	Sorafenib (BAY 43-9006)FDA Link 08/2013
1	Sirolimus (Rapamycin)FDA Link 01/2013
1	Ribosomal Protein S6IBA 01/2013

Therapy/Procedure

14	Therapeutics 10/2022 - 01/2016
6	Precision Medicine 04/2022 - 09/2015
5	Drug Therapy (Chemotherapy) 01/2019 - 08/2013
3	Immunotherapy 03/2021 - 01/2017
2	Aftercare (After-Treatment) 01/2016 - 01/2013
1	Prostatectomy (Retropubic Prostatectomy) 09/2021
1	Biological Therapy 06/2017
1	Radiotherapy 01/2017